| abstract |
The compounds of the present invention, intended for the treatment of pathological conditions or diseases in which one or more of the somastatin receptors are involved, correspond to the following general formula (1) in which: R1 in particular represents an optionally heterocyclic or carbocyclic aryl radical substituted or an optionally substituted non-aromatic heterocyclic radical; R2 represents H, optionally substituted alkyl or aryl; R3 represents H or - (CH2) p -Z3; Z3 represents in particular alkyl, cycloalkyl, bis-arylalkyl or di-arylalkyl, -Y1- (CH2) p-phenyl- (X1) n, optionally substituted carbocyclic or heterocyclic unaryl, an optionally substituted non-aromatic heterocyclic radical; X1, each time it is presented, is independently selected from radicals H, Cl, F, Br, I, CH3, NO2, OH, NH2, CH, N3, -OCF3, alkyl, alkoxy, S-alkyl - (CH2) p-NH2, - (CH2) p-NH-alkyl and (CH2) pN-dialkyl; Y1 represents O, S, NH or lack; R4 represents - (CH2) pZ4; Z4 represents in particular amino, alkyl amino or N, N-dialkyl amino; R5 represents in particular H or alkyl; X represents O or S; p, each time it is presented, is independently 0 or an integer from 1 to 6; q, each time it is presented, it is independently an integer from 1 to 5; n represents 0 or 1; assuming that when n represents 0, m represents 1.2 or 3 and when n represents 1, m represents 0 or 1. |